Haemonetics (HAE) Net Income towards Common Stockholders (2009 - 2026)

Haemonetics has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $33.0 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 3.11% year-over-year to $33.0 million in Q2 2026; TTM through Jun 2026 was $96.3 million, a 41.05% decrease from a year earlier, with the FY2026 full-year figure at $97.3 million, down 41.97% from the prior year.
• Net Income towards Common Stockholders was $33.0 million for Q2 2026 at Haemonetics, up from -$20.1 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $58.0 million in Q1 2025, with the low at -$20.1 million in Q1 2026.
• Average Net Income towards Common Stockholders over 5 years is $29.7 million, with a median of $33.0 million recorded in 2026.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders surged 546.27% in 2022, then sank 134.7% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at $32.9 million in 2022, then dropped by 5.15% to $31.2 million in 2023, then rose by 20.06% to $37.5 million in 2024, then increased by 19.33% to $44.7 million in 2025, then fell by 26.3% to $33.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $33.0 million (Q2 2026), -$20.1 million (Q1 2026), and $44.7 million (Q4 2025), per Business Quant data.